Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Leukemia

  Free Subscription


25.08.2025

1 Am J Clin Pathol
3 Am J Hematol
1 Ann Hematol
2 Blood
1 BMC Cancer
4 Bone Marrow Transplant
2 Br J Haematol
2 Cancer
1 Cancer Chemother Pharmacol
2 Exp Hematol
1 Gene
3 J Clin Oncol
1 J Natl Cancer Inst
2 J Pediatr Hematol Oncol
3 Leuk Lymphoma
4 Leuk Res
4 Leukemia


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. ALJABBAN A, Azevedo RS, Antel K, Arnette A, et al
    Mutational signature analysis of chronic lymphocytic leukemia uncovering genomic patterns and prognostic implications.
    Am J Clin Pathol. 2025 Aug 15:aqaf059. doi: 10.1093.
    PubMed         Abstract available


    Am J Hematol

  2. DUMINUCO A, Venanzi A, Santi A, Mancini A, et al
    Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy.
    Am J Hematol. 2025 Aug 23. doi: 10.1002/ajh.70043.
    PubMed        

  3. CHATILA R, Beziat G, Pirovano L, Bouyssie C, et al
    Partial Nuclear Extrusion in Chronic Lymphocytic Leukemia Observed to Be an In Vitro Artefact.
    Am J Hematol. 2025 Aug 22. doi: 10.1002/ajh.70041.
    PubMed        

  4. OTHMAN T, Baird JH, Wang Y, Pak S, et al
    Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma.
    Am J Hematol. 2025 Aug 20. doi: 10.1002/ajh.70038.
    PubMed        


    Ann Hematol

  5. YANG Y, Zhang X, Jiang N, Jin Y, et al
    Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2025 Aug 26. doi: 10.1007/s00277-025-06535.
    PubMed         Abstract available


    Blood

  6. CHENG W, Yi X, Wang Z, Li JF, et al
    Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
    Blood. 2025 Aug 19:blood.2024027692. doi: 10.1182/blood.2024027692.
    PubMed         Abstract available

  7. ANNESLEY C, Seidel K, Wu Q, Summers C, et al
    Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL.
    Blood. 2025;146:789-801.
    PubMed         Abstract available


    BMC Cancer

  8. KONG M, Yang Y, Wu Z, Li Y, et al
    Leveraging diverse liquid-liquid phase separation patterns to predict the prognosis and immunotherapy of pediatric acute myeloid leukemia.
    BMC Cancer. 2025;25:1326.
    PubMed         Abstract available


    Bone Marrow Transplant

  9. CHEN H, Xu LP, Zhang XH, Wang Y, et al
    Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Bone Marrow Transplant. 2025 Aug 18. doi: 10.1038/s41409-025-02698.
    PubMed        

  10. CHAUVET P, Saade C, Demaret J, Beauvais D, et al
    Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis.
    Bone Marrow Transplant. 2025 Aug 21. doi: 10.1038/s41409-025-02700.
    PubMed        

  11. LI SQ, Xu LP, Wang Y, Zhang XH, et al
    Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.
    Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02699.
    PubMed         Abstract available

  12. O'CONNOR TE, Lin C, Roloff GW, Zhang A, et al
    The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02693.
    PubMed         Abstract available


    Br J Haematol

  13. TINAJERO J, Ngo D, Motta M, Agrawal V, et al
    The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission.
    Br J Haematol. 2025;207:426-431.
    PubMed         Abstract available

  14. BORJA-MONTES OF, Toro-Pedroza A, Epperla N, Andritsos LA, et al
    Hairy cell leukaemia and pregnancy: A systematic review and review of literature.
    Br J Haematol. 2025;207:678-682.
    PubMed         Abstract available


    Cancer

  15. LIAN J, Zhuang X, Chen Y, Lin Q, et al
    Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine.
    Cancer. 2025;131:e70053.
    PubMed         Abstract available

  16. CAIROLI R, Del Castello L, Imbergamo S, Pierdomenico E, et al
    Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.
    Cancer. 2025;131:e70055.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  17. SY SKB, Yang Y, Darstein C, Yoon DY, et al
    Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.
    Cancer Chemother Pharmacol. 2025;95:83.
    PubMed        


    Exp Hematol

  18. YOSHIDA S, Onozawa M, Yokoyama S, Matsukawa T, et al
    Peposertib suppresses generation of FLT3-internal tandem duplication formed by contralateral double nicks.
    Exp Hematol. 2025;149:104819.
    PubMed         Abstract available

  19. SANGHA G, Huntly BJP
    Gene regulatory complexes: their role and regulation across normal and malignant hematopoiesis.
    Exp Hematol. 2025;149:104821.
    PubMed         Abstract available


    Gene

  20. DHIFLAOUI A, Almawi WY
    Mechanisms and clinical implications of microRNA associations and signaling pathways in B-cell acute lymphoblastic leukemia.
    Gene. 2025 Aug 17:149730. doi: 10.1016/j.gene.2025.149730.
    PubMed         Abstract available


    J Clin Oncol

  21. PLATZBECKER U, Ades L, Montesinos P, Ammatuna E, et al
    Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
    J Clin Oncol. 2025 Aug 18:JCO2500535. doi: 10.1200/JCO-25-00535.
    PubMed         Abstract available

  22. ILAND HJ
    APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy.
    J Clin Oncol. 2025 Aug 18:JCO2501496. doi: 10.1200/JCO-25-01496.
    PubMed        

  23. DINARDO CD, Marvin-Peek J, Loghavi S, Takahashi K, et al
    Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
    J Clin Oncol. 2025;43:2692-2699.
    PubMed         Abstract available


    J Natl Cancer Inst

  24. ZHENG DJ, Hettinger G, Aftandilian C, Bona K, et al
    Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.
    J Natl Cancer Inst. 2025 Aug 20:djaf234. doi: 10.1093.
    PubMed         Abstract available


    J Pediatr Hematol Oncol

  25. KURTIPEK FB, Damar C, Gokcek E, Gulhan B, et al
    Rare Pancreatitis-Related Complications of L-Asparaginase in Pediatric Acute Lymphoblastic Leukemia: A Case With Pseudocyst and Panniculitis and Literature Review.
    J Pediatr Hematol Oncol. 2025 Aug 25. doi: 10.1097/MPH.0000000000003110.
    PubMed         Abstract available

  26. KANG J, Kanukollu S, Bevinetto A, Corless R, et al
    Comparing Tolerability and Toxicity of Calaspargase-Pegol and Pegaspargase in Pediatric Leukemia Patients.
    J Pediatr Hematol Oncol. 2025 Aug 22. doi: 10.1097/MPH.0000000000003098.
    PubMed         Abstract available


    Leuk Lymphoma

  27. AMIRI D, Mirzaei M, Bahri T, Barkhordar M, et al
    Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen.
    Leuk Lymphoma. 2025 Aug 20:1-9. doi: 10.1080/10428194.2025.2548968.
    PubMed         Abstract available

  28. LIPTON JH
    Indolent chronic myeloid leukemia - a historical dinosaur?
    Leuk Lymphoma. 2025 Aug 22:1-2. doi: 10.1080/10428194.2025.2536121.
    PubMed        

  29. TESSIER S, Greipp PT, Jevremovic D, Alkhateeb HB, et al
    Acute leukemia of ambiguous lineage with KMT2A-alterations in adults.
    Leuk Lymphoma. 2025 Aug 25:1-6. doi: 10.1080/10428194.2025.2547988.
    PubMed        


    Leuk Res

  30. RAVIPATI S, Bakheet W, Woldie I, Gupta R, et al
    Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia.
    Leuk Res. 2025;157:108087.
    PubMed         Abstract available

  31. ZHANG TY, Ge AY, Epstein MM, Patel SA, et al
    Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study.
    Leuk Res. 2025;157:108086.
    PubMed         Abstract available

  32. FATHI AT, Smith BD, Angiolillo A, Binder G, et al
    Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial.
    Leuk Res. 2025;157:107925.
    PubMed        

  33. KELLAWAY SG
    Targeting growth signals in leukemia: A case of mistaken identity.
    Leuk Res. 2025;157:107935.
    PubMed        


    Leukemia

  34. TELZEROW E, Gorlich D, Sauerland C, Rothenberg-Thurley M, et al
    Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.
    Leukemia. 2025 Aug 22. doi: 10.1038/s41375-025-02735.
    PubMed         Abstract available

  35. ZHENG J, Jin L, Chen Y, Duan Y, et al
    Targeting p16(INK4a)-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia.
    Leukemia. 2025 Aug 21. doi: 10.1038/s41375-025-02743.
    PubMed         Abstract available

  36. FERRAO BLANCO MN, Kazybay B, Belderbos M, Heidenreich O, et al
    Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment.
    Leukemia. 2025 Aug 15. doi: 10.1038/s41375-025-02734.
    PubMed         Abstract available

  37. AMARAL P, Christie R, Gresham DOF, Lucas EJM, et al
    Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.
    Leukemia. 2025 Aug 14. doi: 10.1038/s41375-025-02723.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.